Helixgate https://validator.w3.org/feed/docs/rss2.html Unforced errors flummox HHS’ radical transparency bid—again Avalo shares spike on skin drug data; BioNTech to cut staff Novo’s Wegovy pill reaches 1M patients, shattering expectations with $355M in sales GSK goes to China for $1B siRNA deal in Arrowhead’s obesity lane STAT+: Novo Nordisk’s less-bad news on its Wegovy pill boosts earnings and share price Bayer ends multi-year M&A drought with up to $2.45B Perfuse buy Viridian turns green again as new Phase 3 data vindicate thyroid eye disease drug Novelty Nobility Expands AGC Biologics Deal to Take Product Candidate Through GMP Manufacturing J&J pushes dual-antibody IBD therapy into Phase 3 despite mid-stage fails HHS tackles ‘overmedication’ Makary defends Replimune melanoma rejection again as FDA tensions build CellCentric raises $220M to get multiple myeloma pill to market Pfizer, Lilly, more report Q1, FDA names acting CBER director and an ALS awakening Novo Nordisk’s Q1 in four words: Pills, pricing, payments and pressure Opinion: Dr. Glaucomflecken wants to make a stink STAT+: Even at a meeting in Rome, FDA shifts are top of mind for gene therapy field Founders face pressure from all sides as biotech crawls toward recovery J&J’s Ottava surgical robot meets primary endpoints in gastric bypass study UCB to Acquire Candid for up to $2.2B, Expanding Presence in TCE Antibodies for Immunology Home Chromosome Engineering Reveals New Locus for Fusarium Resistance in Wheat STAT+: Did AI really beat doctors at diagnosis? Psilocybin-Induced Brain Changes May Explain Therapeutic Effects Intercept’s next-gen FXR agonist fails Phase 2 in latest setback for Italian-owned pharma Pfizer’s Albert Bourla says he has no mega-merger plans STAT+: Pharma’s reputation among patient groups rose last year, but concerns remain over access and pricing STAT+: A new attack on AMA’s billing codes BioNTech to scale down manufacturing, over 1,800 jobs on the line Viridian data lift prospects for thyroid eye disease drug Pfizer is a 2029 story but Q126 lays foundation for growth Second life for gene therapy; Takeda Phase 2/3 win; UK cancer biotech’s $83M After Arcellx buyout close, Gilead trims 108 jobs at CAR-T biotech’s Redwood City outpost Swiss manufacturing, biotech industry so far unfazed by geopolitics STAT+: Are analysts too quick to gloss over Lilly’s liver case? BioNTech moves to close multiple manufacturing plants, affecting 1,860 jobs QurAlis’ Phase 2 data bolster case for genetic approach to sporadic ALS Madrigal extends MASH deal streak with Arrowhead drug that J&J didn’t want STAT+: Pharmalittle: We’re reading about RFK Jr. targeting antidepressants, J&J pushing an IBD drug, and more Vertex earnings get muted investor response Vertex’s quiet Q1 is calm before potentially ‘iconic’ renal evolution Foundayo’s liver failure blip weighs down Lilly shares. but analysts unconcerned New Human-Computer Interaction Software Designed to Support Diverse Online Teamwork Styles What you need to know about hantavirus (don’t panic) FDA uncertainty persists as search for Prasad successor at CBER drags on Cytokinetics succeeds where Bristol Myers failed in heart muscle disease Genomics and Greywolf partner on autoimmune disease treatments  STAT+: Top lawmaker takes aim at doctor lobby, linking AMA’s billing codes to fraud fight IPF draws investor heat as biotechs target fibrosis halt, better tolerability Cytospire hauls in $83M for a new type of T cell engager STAT+: Johnson & Johnson advances IBD therapy, despite trial miss